Now, Moderna's mRNA RSV shot has been given Breakthrough Therapy Designation, which allows for faster development and an expedited review period

RSV is usually not serious; most people experience only mild, cold-like symptoms and recover on their own in a week or two

Moderna plans to file for FDA approval of mRNA-1345 in the first half of 2023

Along with Moderna's mRNA RSV shot, Pfizer and GSK have also developed RSV vaccines that are awaiting regulatory approval

Get ready. A new mRNA shot is barreling down the runway and may be available as soon as fall 2023. This time, it's not to target SARS-CoV-2 but, rather, respiratory syncytial virus (RSV), a pathogen that typically causes mild cold-like symptoms.

Pfizer and Moderna are racing to bring their RSV shots to market, and Moderna just moved one step closer with its mRNA-1345. The U.S. Food and Drug Administration (FDA) granted the experimental shot fast-track designation in August 2021. Now, Moderna's mRNA RSV shot has been given Breakthrough Therapy Designation, which allows for faster development and an expedited review period.1

WEF Warns of RSV 'Tripledemic'